Junshi Biosciences Says Toripalimab Combination Cuts Death Risk 34% in Phase 3 Trial
Junshi Biosciences reported that toripalimab plus chemotherapy cut death risk by 34% in a Phase 3 lung cancer trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.